In this study, the management of patients with FIGO stage IIB-IVA cervical cancers using radiotherapy alone, and concurrent chemoradiotherapy and weekly cisplatin theraphy were evaluated regarding their treatment efficacy. The study was conducted on 40 patients with FIGO stage IIB-IVA cervix cancer, administered to fiiflli Etfal Research and Education Hospital, Department of Radiation Oncology between January 2003 and December 2006. All patients had pathological proof of their diseases . Twenty of these patients had conventional pelvic radiotherapy (50-60 Gy total, 1.8-2 Gy x 5 days/week), concurrent cisplatin treatment (40 mg/m2/week) during 5 weeks, followed by intracavitary brachytherapy (2000-2750 cGy to point A). Remaining 20 patients had conventional radiotheraphy alone (50-60 Gy) followed by intracavitary brachytheraphy (2000- 2750 cGy to point A). The average disease free survival time was 48 months (71.85%) after combined therapy, and 41 months (65.78%) after radiotherapy alone. The average overall survival time was 51.4 months (78.25%) in combined therapy, and 45.5 months (69.31%) in radiotherapy alone. There was no significant difference between two treatment options regarding disease free survival period and overall survival time. Concurrent chemoradiotherapy is preferred in selected patients due to the high response rate and acceptable toxicity. However, we have not and difference between concurrent radiotherapy or radiotherapy alone regarding survival times, possibly due to statistical inadequacy of the number of our patients.

Keywords: Uterine cervical neoplasms, Cisplatin, Radiotherapy